{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-307296","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2022-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.226424+00:00","generated_at":"2026-06-21T03:31:16.277095+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lyell Immunopharma appoints Lynn Seely as President and CEO, succeeding Elizabeth Homans","bullets":["Elizabeth Homans steps down as CEO effective Dec 15, 2022; will remain as consultant through June 2024.","Homans receives $900k base salary severance (18 months), $360k target bonus, continued option vesting, COBRA.","Lynn Seely appointed President and CEO; annual base salary $650k, target bonus 60%, and option for 7.5M shares.","Seely previously CEO of Myovant Sciences and CMO of Medivation; joined Lyell Board in May 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-307296","json":"https://secwatch.observer/filing/0001193125-22-307296.json","markdown":"https://secwatch.observer/filing/0001193125-22-307296.md","text":"https://secwatch.observer/filing/0001193125-22-307296.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000119312522307296/0001193125-22-307296-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000119312522307296/d438667d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T03:31:16.277095+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2ad474fd8c","claim":"Elizabeth Homans resigned as Chief Executive Officer at Lyell Immunopharma, Inc..","evidence_excerpt":"On December 15, 2022, Lyell Immunopharma, Inc. (the “Company”) announced that Ms. Elizabeth Homans would step down from her position as Chief Executive Officer and as a member of the Board of Directors (the “Board”) of the Company effective December 15, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312522307296/0001193125-22-307296-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"94fc373c49","claim":"Lynn Seely was appointed as President and Chief Executive Officer at Lyell Immunopharma, Inc..","evidence_excerpt":"On December 14, 2022, Dr. Seely entered into an offer of employment with the Company (the “Seely Offer Letter”), pursuant to which she commenced her role as the Company’s President and Chief Executive Officer on December 15, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312522307296/0001193125-22-307296-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}